A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: FRONTIER-4
Interleukin-33 may have a role in COPD pathobiology. FRONTIER-4 (NCT04631016) investigated tozorakimab (an anti-IL-33 monoclonal antibody) in moderate-to-severe COPD patients with chronic bronchitis receiving dual or triple inhaled therapy. FRONTIER-4 was a phase 2a, randomized, double-blind, placeb...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | 英语 |
| 出版: |
2025
|
| 在線閱讀: | https://doi.org/10.1183/13993003.02231-2024 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|